001440164 000__ 03301cam\a2200565\i\4500
001440164 001__ 1440164
001440164 003__ OCoLC
001440164 005__ 20230309004545.0
001440164 006__ m\\\\\o\\d\\\\\\\\
001440164 007__ cr\cn\nnnunnun
001440164 008__ 211005s2021\\\\sz\a\\\\o\\\\\001\0\eng\d
001440164 019__ $$a1272956512$$a1273076388$$a1273121564
001440164 020__ $$a9783030740283$$q(electronic bk.)
001440164 020__ $$a3030740285$$q(electronic bk.)
001440164 020__ $$z9783030740276
001440164 020__ $$z3030740277
001440164 0247_ $$a10.1007/978-3-030-74028-3$$2doi
001440164 035__ $$aSP(OCoLC)1273413815
001440164 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dYDX$$dOCLCO$$dEBLCP$$dOCLCF$$dN$T$$dUKAHL$$dOCLCQ$$dCOM$$dOCLCO$$dOCLCQ
001440164 049__ $$aISEA
001440164 050_4 $$aRC280.L8
001440164 08204 $$a616.99/424$$223
001440164 24500 $$aLung cancer :$$bnew understandings and therapies /$$cAnne C. Chiang, Roy S. Herbst, editors.
001440164 264_1 $$aCham, Switzerland :$$bSpringer,$$c2021.
001440164 300__ $$a1 online resource (vi, 264 pages) :$$billustrations (some color)
001440164 336__ $$atext$$btxt$$2rdacontent
001440164 337__ $$acomputer$$bc$$2rdamedia
001440164 338__ $$aonline resource$$bcr$$2rdacarrier
001440164 4901_ $$aCurrent cancer research,$$x2199-2592
001440164 500__ $$aIncludes index.
001440164 5050_ $$aTumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
001440164 506__ $$aAccess limited to authorized users.
001440164 520__ $$aLung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
001440164 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed October 5, 2021).
001440164 650_0 $$aLungs$$xCancer.
001440164 650_0 $$aLungs$$xCancer$$xTreatment.
001440164 650_6 $$aPoumons$$xCancer.
001440164 650_6 $$aPoumons$$xCancer$$xTraitement.
001440164 655_0 $$aElectronic books.
001440164 7001_ $$aChiang, Anne C.,$$eeditor.
001440164 7001_ $$aHerbst, Roy,$$eeditor.
001440164 77608 $$iPrint version:$$z9783030740283
001440164 77608 $$iPrint version:$$z3030740277$$z9783030740276$$w(OCoLC)1241732686
001440164 830_0 $$aCurrent cancer research,$$x2199-2592
001440164 852__ $$bebk
001440164 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-74028-3$$zOnline Access$$91397441.1
001440164 909CO $$ooai:library.usi.edu:1440164$$pGLOBAL_SET
001440164 980__ $$aBIB
001440164 980__ $$aEBOOK
001440164 982__ $$aEbook
001440164 983__ $$aOnline
001440164 994__ $$a92$$bISE